TY - JOUR
T1 - Use of proton pump inhibitors and risk of rosacea
T2 - A nationwide population-based study
AU - Dai, Ying Xiu
AU - Tai, Ying Hsuan
AU - Chen, Chih Chiang
AU - Chang, Yun Ting
AU - Chen, Tzeng Ji
AU - Chen, Mu Hong
N1 - Funding Information:
This study was funded by the Ministry of Science and Technology, China, under grant no. MOST 107‐2314‐B‐075‐032‐MY3‐2.
Publisher Copyright:
© 2020 Japanese Dermatological Association
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Proton pump inhibitors (PPI) are commonly used drugs. However, little is known about the association between PPI use and rosacea. This study aimed to investigate the association between PPI use and rosacea risk. Patients with prior PPI therapy, including 1067 rosacea cases and 4268 matched controls, were identified from the National Health Insurance Research Database in Taiwan. The cumulative defined daily dose (cDDD) was used to quantify the PPI use. Logistic regression was used for the analyses. After adjustment for potential confounders, PPI use with cDDD of more than 365 was significantly associated with an increased risk of rosacea (odds ratio [OR], 1.54; 95% confidence interval [CI], 1.10–2.15). Rosacea risk was significantly associated with PPI use of cDDD of more than 365 in women (OR, 1.62; 95% CI, 1.08–2.46) but not in men. Stratified by PPI indications, risk of rosacea was significantly associated with PPI use of cDDD of more than 365 for peptic ulcer (OR, 1.58; 95% CI, 1.12–2.21). In conclusion, prolonged PPI use was associated with an increased risk of rosacea, particularly in women and patients with peptic ulcers.
AB - Proton pump inhibitors (PPI) are commonly used drugs. However, little is known about the association between PPI use and rosacea. This study aimed to investigate the association between PPI use and rosacea risk. Patients with prior PPI therapy, including 1067 rosacea cases and 4268 matched controls, were identified from the National Health Insurance Research Database in Taiwan. The cumulative defined daily dose (cDDD) was used to quantify the PPI use. Logistic regression was used for the analyses. After adjustment for potential confounders, PPI use with cDDD of more than 365 was significantly associated with an increased risk of rosacea (odds ratio [OR], 1.54; 95% confidence interval [CI], 1.10–2.15). Rosacea risk was significantly associated with PPI use of cDDD of more than 365 in women (OR, 1.62; 95% CI, 1.08–2.46) but not in men. Stratified by PPI indications, risk of rosacea was significantly associated with PPI use of cDDD of more than 365 for peptic ulcer (OR, 1.58; 95% CI, 1.12–2.21). In conclusion, prolonged PPI use was associated with an increased risk of rosacea, particularly in women and patients with peptic ulcers.
KW - case–control study
KW - epidemiology
KW - proton pump inhibitors
KW - rosacea
KW - Taiwan’s National Health Insurance Research Database
UR - http://www.scopus.com/inward/record.url?scp=85087287582&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087287582&partnerID=8YFLogxK
U2 - 10.1111/1346-8138.15478
DO - 10.1111/1346-8138.15478
M3 - Article
C2 - 32613686
AN - SCOPUS:85087287582
SN - 0385-2407
VL - 47
SP - 1126
EP - 1130
JO - Journal of Dermatology
JF - Journal of Dermatology
IS - 10
ER -